ArticleFrontiers in oncology2025
Prognostic value of metastatic lymph node ratio and its effect on disease-free survival in colon cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The metastatic lymph node ratio (MLNR) has been proposed as a meaningful prognostic indicator in colon cancer (CC). This study aimed to assess the prognostic relevance of MLNR by investigating its association with disease-free survival (DFS), overall survival (OS), and recurrence, and to compare its predictive value with traditional parameters, including the TNM classification and total lymph node count (TNLC). Materials and methods: This retrospective, single-center study included patients who underwent surgical resection for colon cancer. Survival outcomes were analyzed using Kaplan-Meier survival curves and multivariate logistic regression. MLNR was evaluated in relation to demographic and clinical factors, including age, tumor location, surgical type, and the administration of adjuvant chemotherapy. The optimal MLNR cut-off value for predicting recurrence was determined via receiver operating characteristic (ROC) curve analysis. Results: A total of 122 patients were analyzed. MLNR >0.125 was significantly associated with increased recurrence risk (adjusted HR: 7.0, p<0.001) and reduced DFS. Patients with an MLNR ≤0.125 demonstrated significantly longer DFS (p<0.001). MLNR emerged as an independent prognostic factor, offering potential prognostic benefit compared to TNLC in predicting both DFS and OS. Additionally, adjuvant chemotherapy was independently associated with a lower recurrence risk (Exp(B):0.234, p=0.038). Emergency surgery was found to be significantly correlated with poorer survival outcomes (p=0.023). Conclusion: MLNR contributes additional prognostic information to the TNM staging system and may support more individualized risk stratification and decision-making regarding adjuvant therapy in colon cancer. Further large-scale prospective studies are warranted to validate these findings and to establish a clinically applicable MLNR threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.